Lab Vacancy Is Rising. Compliant Storage Capacity Is Not.
What the 2026 Life Sciences Real Estate Rebound Actually Means for Manufacturers Who Need Storage Space
Cushman & Wakefield’s February 2026 Life Sciences Update reported global lab and cGMP rents softening 1.7 percent year over year, with vacancy climbing to 23.1 percent as newly delivered space outpaced demand. Read on its own, that data point suggests the life science real estate crunch of the past several years is easing. For manufacturers who need FDA-registered, cGMP-compliant storage for raw materials, work-in-process inventory, or finished goods, it is a misleading signal. Lab vacancy and compliant manufacturing storage are not the same market, and the forces keeping one tight have not moved with the other.
This article breaks down why that gap exists, what is actually driving storage demand for manufacturers in 2026, and what a real capacity plan should account for before internal storeroom space or a production timeline forces the decision.
Why This Matters Operationally: A manufacturer that reads ‘life science real estate is loosening’ and delays a storage decision is reading the wrong market. Rising lab vacancy reflects a wave of speculative research space built during 2021 to 2023. It says nothing about whether compliant warehouse racking, environmental monitoring, and audit-ready documentation are available where and when a production ramp needs them.
Two Different Real Estate Markets Wearing One Label
“Life science real estate” gets reported as a single category, but storage for manufacturers and lab space for research draw on different supply. Lab vacancy rose because investor-driven construction from the pandemic years caught up with slower demand. Boston, San Francisco, and San Diego all saw occupancy fall from the mid-90s in 2022 into the 70s and 80s by 2025 as speculative lab inventory came online faster than tenants could absorb it.
Manufacturing and warehouse storage did not see that same construction wave. Space that needs FDA registration under 21 CFR Part 207, cGMP compliance under 21 CFR Parts 210 and 211, and continuously monitored environmental controls is harder and slower to build than a shell lab building. That gap in supply response is a large part of why 3PL providers serving this sector continue to report demand outpacing new capacity almost as soon as it opens.
Where the Assumption Breaks Down
The table below separates what manufacturers commonly assume from what actually determines whether compliant storage is available when they need it.
| Storage Element | What Manufacturers Assume | What Actually Determines It |
|---|---|---|
| Lab vacancy | Rising lab vacancy means real estate pressure is easing across life sciences broadly | Lab vacancy and cGMP warehouse capacity are separate markets; one loosening does not free up the other |
| FDA Registration | A warehouse that is FDA-registered is automatically ready to store regulated materials | Registration is a precondition, not a substitute for demonstrated environmental monitoring and documentation practices |
| General industrial space | Any warehouse with racking and climate control can be adapted for life science storage | cGMP storage requires continuous monitoring, excursion management, and audit-ready recordkeeping built into daily operations |
| Internal storeroom capacity | Production floor storage can absorb growth as manufacturing scales | New production lines and expanded product mixes routinely consume storeroom footprint faster than facilities can expand it |
| Timeline to compliant space | Outsourced storage can be arranged on short notice once a need is identified | Facility qualification, documentation review, and onboarding take lead time; waiting until capacity is exhausted narrows the options |
What Is Actually Driving Storage Demand in 2026
A few forces are converging at the same time lab vacancy is loosening, which is why the two trends can move in opposite directions.
The Shift from R&D to Commercialization
As more early-stage biotech and device companies move from pilot production into full manufacturing, they hit an operational wall that lab space never prepared them for. Companies that scaled their science are frequently unprepared for the compliance and space requirements of scaling their supply chain.
Onshoring Pressure
Proposed pharmaceutical tariffs and continued supply chain uncertainty are pushing manufacturers to bring production and storage closer to home rather than relying on overseas facilities. That directly increases demand for domestic cGMP-compliant warehouse space, independent of what is happening in the lab leasing market.
Tighter Internal Storeroom Capacity
The pressure is not limited to external real estate. New production lines and expanded product mixes are consuming storeroom footprint on manufacturers’ own floors, pushing companies to look at outsourcing overflow and safety stock storage rather than absorbing more shelving into an already strained layout.
Regulatory Expectations Have Not Eased
2026 has continued to reinforce what “current” means in cGMP: facilities need to demonstrate up-to-date environmental monitoring, documented excursion management, and audit-ready recordkeeping, not just meet a static checklist from years ago. That raises the bar for what counts as adequate storage and rules out a lot of generic warehouse space as a real option.
What a Complete Storage Capacity Plan Should Include
Before committing to a storage arrangement, manufacturers should independently verify the following, rather than relying on square footage and price per pallet alone.
Verification Required Before Committing to a Facility
- Confirm the facility’s current FDA registration under 21 CFR Part 207, verified directly rather than taken on the provider’s word.
- Review documented environmental monitoring records, including temperature and humidity excursion history, not just a stated policy.
- Confirm the quality management program covers the specific product category being stored, not a generic warehousing standard.
- Assess available capacity against near-term production growth, not just current volume.
- Establish the lead time required for onboarding, so a capacity decision is not made under deadline pressure.
Why Mid-Size Manufacturers Feel This Most
Large pharmaceutical companies typically have the capital to build or lease purpose-built facilities on their own timeline. The squeeze is felt hardest by mid-size manufacturers and companies transitioning from clinical to commercial stage, who need outsourced storage that is already compliant, already registered, and ready to scale without a multi-year buildout.
For these companies, waiting for broader life science real estate headlines to translate into easier warehouse access means waiting on the wrong signal. The practical move is to start the storage conversation twelve to twenty-four months before the internal storeroom or production timeline forces the issue.
How Euro-American Worldwide Logistics Supports Storage Capacity Planning
Euro-American Worldwide Logistics maintains FDA-registered, cGMP-compliant warehouse space built for pharmaceutical, biotech, and medical device manufacturers, with continuous temperature and humidity monitoring and documented excursion management built into standard operations. Our team works with clients to structure storage capacity around production timelines, so a scale-up in manufacturing does not stall out waiting on a real estate search.
For manufacturers evaluating a transition from internal storeroom space to outsourced storage, or reassessing an existing arrangement against current cGMP documentation expectations, we can walk through facility qualification and compliance recordkeeping before a storage agreement is signed.
If you would like to review your current storage capacity planning or discuss space for an upcoming production ramp, contact our team today.
This article references Cushman & Wakefield’s February 2026 Life Sciences Update and current FDA cGMP requirements under 21 CFR Parts 210 and 211. Facility-specific compliance status should be verified directly with any storage provider before a storage agreement is finalized.
